scholarly journals Photodynamic Therapy for 101 Early Cancers of the Upper Aerodigestive Tract, the Esophagus, and the Bronchi: A Single-Institution Experience

1999 ◽  
Vol 5 (3) ◽  
pp. 145-154 ◽  
Author(s):  
A. Radu ◽  
P. Grosjean ◽  
Ch. Fontolliet ◽  
G. Wagnieres ◽  
A. Woodtli ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Early Stage ◽  
Red Light ◽  
Green Light ◽  
Tracheobronchial Tree ◽  
Aerodigestive Tract ◽  
Upper Aerodigestive Tract ◽  
Photofrin Ii ◽  
Significant Difference ◽  
Radical Therapy

Cancer, when detected at an early stage, has a very good probability of being eradicated by surgery or radiotherapy. However, less aggressive treatments also tend to provide high rates of cure without the side effects of radical therapy. We report on the results of our clinical experience with photodynamic therapy (PDT) for the treatment of early carcinomas in the upper aerodigestive tract, the esophagus, and the tracheobronchial tree. Sixty-four patients with 101 squamous cell carcinomas were treated with three different photosensitizers: hematoporphyrin derivative (HPD), Photofrin II, and tetra (m-hydroxyphenyl)chlorin (mTHPC). Seventy-seven (76%) tumors showed a complete rsponse with no recurrence after a mean follow-up period of 27 months. There was no significant difference in terms of cure rates among the three dyes. However, mTHPC has a stronger phototoxicity and induces a shorter skin photosensitization than either of the other photosensitizers. There were eight major complications: three esophagotracheal fistulae after illumination with red light in the esophagus, two esophageal stenoses following 360° circumferential irradiation, and three bronchial stenoses. Illumination with the less penetrating green light and the use of a 180° or 240° windowed cylindrical light distributor render the risk of complications in the esophagus essentially impossible, without reducing the efficacy of the treatment. Therefore, PDT may be considered as a safe and effective treatment for early carcinomas of the upper aerodigestive tract, the esophagus, and the tracheobronchial tree.

Photodynamic therapy in the upper aerodigestive tract. Overview and outlook

2016 ◽  
Vol 9 (11-12) ◽  
pp. 1302-1313 ◽  
Author(s):  
Veronika Volgger ◽  
Christian Stephan Betz
Keyword(s):  
Photodynamic Therapy ◽  
Aerodigestive Tract ◽  
Upper Aerodigestive Tract

Green light is effective and less painful than red light in photodynamic therapy of facial solar keratoses

1997 ◽  
Vol 13 (5-6) ◽  
pp. 181-185 ◽  
Author(s):  
C. Fritsch ◽  
H. Stege ◽  
G. Saalmann ◽  
G. Goerz ◽  
T. Ruzicka ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Red Light ◽  
Green Light

scholarly journals Fricke Dosimetry as a Tool to Quality Control of Photodynamic Therapy

2019 ◽  
Vol 7 (3) ◽  
Author(s):  
SUZANA OLIVEIRA SANTOS ◽  
Vivianne L. B. Souza
Keyword(s):  
Quality Control ◽  
Photodynamic Therapy ◽  
Low Cost ◽  
Red Light ◽  
Green Light ◽  
Yellow Light ◽  
Light Emitting ◽  
Low Toxicity ◽  
Cellular Necrosis ◽  
Photosensitizing Agent

Photodynamic therapy (PDT) consists of the association of a photosensitizing agent with a light source in order to cause cellular necrosis. Methylene blue, toluidine blue and malachite green are photosensitizers derived from dyes that are widely accepted in medicine, as they have low toxicity and are low cost. PDT is an alternative treatment for cancer, with significant advantages over procedures such as surgery/chemotherapy. Our laboratory has studied the Fricke solution doped with photosensitizers in an approach to obtain a quality control for PDT. The Fricke solution was prepared with ammoniacal ferrous sulfate, sodium chloride and sulfuric acid in water. The solutions modified with photosensitizers were prepared by adding 0.1 g/100 mL of the dyes. A volume of 2.6 ml of the Fricke solution modified with photosensitizers were transferred to test tubes and irradiated. The irradiated solutions had their optical densities measured in a spectrophotometer. The samples were irradiated with LED (Light Emitting Diodes) in acrylic phantoms. The FATA samples irradiated with LED showed the sensitivity of the dosimeters to red, blue, green and yellow light. A calibration curve with correlation coefficient of 0.9884 for the red light was obtained; 0.9752 for blue light; 0.9644 for the green light and 0.9768 for the yellow light. The fact that a sensitivity of the dosimeters to the LED has been occurred indicates that the PDT could be realized with LED, with lower costs than with laser. This work suggested that FATA dosimeters can be used for quality control of PDT.

The effect of two BRM promoter variants on the risk of stage I/II upper aerodigestive tract cancers.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 10522-10522 ◽  
Author(s):  
Kit Man Wong ◽  
Xiaoping Qiu ◽  
Dangxiao Cheng ◽  
Abul Kalam Azad ◽  
Prakruthi R. Palepu ◽  
...  
Keyword(s):  
Head And Neck ◽  
Histone Deacetylases ◽  
Early Stage ◽  
Smoking Status ◽  
Suppressor Gene ◽  
Aerodigestive Tract ◽  
Stage I ◽  
Upper Aerodigestive Tract ◽  
Putative Tumor Suppressor Gene ◽  
Upper Aerodigestive Tract Cancers

10522 Background: BRM is a key subunit of the chromatin remodeling complex SWI/SNF and a putative tumor suppressor gene that is silenced in 15-20% of many solid tumors (PMID 15722796). Evidence suggests that it is epigenetically regulated, as two BRM promoter insertion variants (BRM-741 and BRM-1321) may lead to gene silencing by recruiting histone deacetylases. The presence of both homozygous BRM-741 and BRM-1321 highly correlate with loss of BRM expression and function in lung tumors, while increasing smoking-related lung cancer by two-fold (PMID 21478907). Also, the pharmacologic reversal of epigenetic changes of BRM offers a potential novel therapeutic approach (PMID 21478905). We assessed whether these BRM variants are associated with the risk of upper aerodigestive tract cancers, focusing on Stage I/II tumors that would most benefit from new screening and prevention strategies. Methods: BRM was genotyped by qPCR using TaqMan probes. 1,008 controls were matched to 595 cases by frequency distribution based on age, gender and smoking status. Multivariate logistic regression generated adjusted odds ratios (aOR). Results: The 595 cases were: 115 esophageal, 278 lung, and 202 head and neck cancers. 51% were adenocarcinomas; 60% were Stage I. The frequency of homozygozity was: BRM-741, 26%; BRM-1321, 23%; both variants, 15%. In the combined analysis, there was significant correlation between malignancy and homozygous BRM-741 (aOR 1.91 (95%CI 1.3-2.4); p=0.001) or BRM-1321 (aOR 1.94 (95%CI 1.4-2.7; p=3x10E-4). Being homozygous for both BRM variants carried an even greater risk (aOR 2.45 (95%CI 1.6-3.9); p=1x10E-5). This correlation was similar for adenocarcinomas (aOR 2.53 (95%CI 1.4-4.2); p=6x10E-4) and squamous cell carcinomas (aOR 2.33 (95%CI 1.3-4.4); p=8x10E-4). The increased cancer risk was also similar between these subgroups: head and neck, esophageal and lung cancers; Stage I and II patients; smokers and non-smokers. Conclusions: The two homozygous BRM variants increase the risk of early stage upper aerodigestive tumors by more than two-fold independent of smoking status. BRM promoter variants and their potential epigenetic effect may be early events in the evolution of these cancers.

Photodynamic Therapy for Cancer of the Upper Aerodigestive Tract Using Tetra(m-hydroxyphenyl)chlorin

1996 ◽  
Vol 14 (5) ◽  
pp. 281-287 ◽  
Author(s):  
PIERRE GROSJEAN ◽  
JEAN-FRANÇOIS SAVARY ◽  
JÉRÔME MIZERET ◽  
GEORGES WAGNIERES ◽  
ALAIN WOODTLI ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Aerodigestive Tract ◽  
Upper Aerodigestive Tract
Sign in / Sign up

Export Citation Format

Share Document